Global pharma giants Pfizer and Mylan have announced that they are combining two of their businesses: Pfizer will spin off its generics drug business and combine it with Mylan, which has a tie-up with India's Biocon. Kiran Mazumdar Shaw, CMD of Biocon, assessed the impact on Indian pharma.
Global pharma giants Pfizer and Mylan
have announced that they are combining two of their businesses: Pfizer will spin off its generics drug business and combine it with Mylan, which has a tie-up with India's Biocon. Kiran Mazumdar Shaw, CMD of Biocon, assessed the impact on Indian pharma.
“Certainly nothing changes for us in terms of our business with Mylan because this actually offers us a much larger opportunity. In yesterday’s presentation, you can see that the combined entity actually is going to rely on a pretty decent contribution from biosimilars and they have mentioned the biosimilar that we are currently commercialising with Mylan, which is Ogivri that is our biosimilar trastuzumab, fulphila, biosimilar pegfilgrastim and semglee glargine and the biosimilar adalimumab,” Shaw told CNBC-TV18 on Tuesday.
“As far as we are concerned, the way they have projected, the contribution of biosimilars to their 2020 estimates is very reassuring that they expect this to be a large earnings contributor as well to this business. So for us, it is a larger global reach and it is a much larger company and therefore we believe that biosimilars will have an even bigger opportunity with this combined entity," she added.
When asked if at any point Biocon will look to extend its partnership with Mylan, she replied, “We have already indicated that we have added a few biosimilars to the existing Biocon-Mylan partnership and of course there are a few others in late-stage clinical trials. So that will also be commercialised at the earliest.”
“We have also indicated that we would like to pursue the biosimilars opportunity on our own. So we will look at developing a portfolio of biosimilars under the Biocon banner and even if we choose to enter into any select marketing partnerships, of course, we will look at that,” she said.
“The biosimilar opportunity is huge and of course the Pfizer biosimilar portfolio is not parked with Upjohn. However, at the same time you do know that Pfizer has discontinued its biosimilar pipeline. So I think you will have to wait and see how this pans out. Needless to say that biosimilar is a very large opportunity and there is plenty of space for many players at this point in time,” Shaw said.